Drug spun off by AstraZeneca shows promise in hot flashes

A sign is seen at an AstraZeneca site in Macclesfield, central England April 28, 2014.  REUTERS/Darren Staples

US-ASTRAZENECA-MILLENDO-HOT-FLASHES:Drug spun off by AstraZeneca shows promise in hot flashes

LONDON (Reuters) - An experimental drug spun off by AstraZeneca last year to an unlisted U.S. biotech firm could cut menopausal hot flashes by nearly three-quarters, according to results from a small mid-stage clinical trial.

The British drugmaker licensed rights to the medicine, which is given as a pill, to Millendo Therapeutics as part of its strategy to divest non-core drug development.

Findings published on Monday in the Lancet medical journal suggest the arrangement is working well for Millendo, which is backed by venture capitalists. AstraZeneca also holds a stake in the company.

The drug, known as MLE4901, works in a novel way by blocking a chemical called neurokinin B.

Hot flashes or flushes, also known as vasomotor symptoms, have been a problematic field for drug research. Hormone replacement therapy can help some women but the therapy can increase the risk of breast cancer and blood clots.

The new drug targets receptors in the brain and offers a different, non-hormonal approach.

The Phase II study funded by Britain's Medical Research Council and the National Institute for Health Research, found 28 women who suffered seven or more hot flashes a day could cut episodes by up to 73 percent with MLE4901, as well as reducing their severity.

Researchers now need to see if the drug, which is also being tested for polycystic ovary syndrome, is safe and effective over the long term in a larger group of patients.

(Reporting by Ben Hirschler, editing by David Evans)

Related News

SunPower sees intense competition in solar this year

Feb 16, 2017

US-SUNPOWER-RESULTS:SunPower sees intense competition in solar this year

After weird winter, U.S. forecasters see warm, wet spring

Mar 20, 2017

US-USA-SPRING:After weird winter, U.S. forecasters see warm, wet spring

Drugmaker GSK recalling nearly 600,000 asthma inhalers in U.S.

Apr 4, 2017

US-GSK-RECALL:Drugmaker GSK recalling nearly 600,000 asthma inhalers in U.S.

Peaple also read these

SunPower sees intense competition in solar this year

Feb 16, 2017

US-SUNPOWER-RESULTS:SunPower sees intense competition in solar this year

After weird winter, U.S. forecasters see warm, wet spring

Mar 20, 2017

US-USA-SPRING:After weird winter, U.S. forecasters see warm, wet spring

Drugmaker GSK recalling nearly 600,000 asthma inhalers in U.S.

Apr 4, 2017

US-GSK-RECALL:Drugmaker GSK recalling nearly 600,000 asthma inhalers in U.S.

About Us

Get the latest news and have a look at the innovations and technologies that are shaping the future and changing the world here in Futurally.

Contact us: sales@futurally.com